Harborside


Khiron Life Sciences Corp.

CVE: KHRN


Canadian symbol: KHRN.V
US symbol: KHRNF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 25.97M
Enterprise Value 23.63M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)1.41
Price/Book (mrq)0.88
Enterprise Value/Revenue 1.62
Enterprise Value/EBITDA -0.75

Trading Information

Stock Price History

Beta (5Y Monthly) 2.06
52-Week Change 3-61.94%
S&P500 52-Week Change 3-3.39%
52 Week High 30.3350
52 Week Low 30.1050
50-Day Moving Average 30.1217
200-Day Moving Average 30.1890

Share Statistics

Avg Vol (3 month) 3194.98k
Avg Vol (10 day) 374.93k
Shares Outstanding 5216.39M
Implied Shares Outstanding 6N/A
Float 8170.16M
% Held by Insiders 15.12%
% Held by Institutions 11.35%
Shares Short (Jul 28, 2022) 4142.59k
Short Ratio (Jul 28, 2022) 40.93
Short % of Float (Jul 28, 2022) 4N/A
Short % of Shares Outstanding (Jul 28, 2022) 40.07%
Shares Short (prior month Jun 29, 2022) 4159.26k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3May 23, 2018
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2021
Most Recent Quarter (mrq)Mar 30, 2022

Profitability

Profit Margin -226.32%
Operating Margin (ttm)-137.31%

Management Effectiveness

Return on Assets (ttm)-23.92%
Return on Equity (ttm)-78.16%

Income Statement

Revenue (ttm)14.6M
Revenue Per Share (ttm)0.09
Quarterly Revenue Growth (yoy)63.70%
Gross Profit (ttm)6.37M
EBITDA -19.13M
Net Income Avi to Common (ttm)-33.05M
Diluted EPS (ttm)-0.1920
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)5.13M
Total Cash Per Share (mrq)0.03
Total Debt (mrq)2.79M
Total Debt/Equity (mrq)9.45
Current Ratio (mrq)2.54
Book Value Per Share (mrq)0.16

Cash Flow Statement

Operating Cash Flow (ttm)-15.01M
Levered Free Cash Flow (ttm)-10.46M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
KHRN.V
Khiron Life Sciences
4 days ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
2 months ago
KHRN.V
Khiron Life Sciences
2 months ago
KHRN.V
Khiron Life Sciences
2 months ago
KHRN.V
Khiron Life Sciences
2 months ago
KHRN.V
Khiron Life Sciences
2 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
4 months ago
KHRN.V
Khiron Life Sciences
4 months ago
KHRN.V
Khiron Life Sciences
4 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
6 months ago
KHRN.V
Khiron Life Sciences
6 months ago
KHRN.V
Khiron Life Sciences
7 months ago
KHRN.V
Khiron Life Sciences
7 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago
KHRN.V
Khiron Life Sciences
3 years ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts0000
Avg. Estimate0000
Low Estimate0000
High Estimate0000
Year Ago EPS-0.11-0.09N/AN/A
Revenue EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts1112
Avg. Estimate1.9M2.8M8.02M12.79M
Low Estimate1.9M2.8M7.6M12.7M
High Estimate1.9M2.8M7.6M13.1M
Year Ago Sales2.21M2.77M9.58M8.02M
Sales Growth (year/est)-13.90%1.00%-16.30%59.60%
Earnings History2019-06-292019-09-292019-12-302020-03-30
EPS Est.-0.09-0.08-0.09-0.09
EPS Actual-0.11-0.09-0.06-0.08
Difference-0.02-0.010.030.01
Surprise %-22.20%-12.50%33.30%11.10%
EPS TrendCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Current Estimate0000
7 Days Ago-0.07-0.05-0.24-0.11
30 Days Ago-0.07-0.05-0.24-0.11
60 Days Ago-0.07-0.05-0.24-0.11
90 Days Ago-0.07-0.05-0.24-0.11
EPS RevisionsCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Up Last 7 DaysN/A1N/AN/A
Up Last 30 DaysN/A1N/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesKHRN.VIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current YearN/AN/AN/AN/A
Next YearN/AN/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
5.12%% of Shares Held by All Insider
1.35%% of Shares Held by Institutions
1.42%% of Float Held by Institutions
3Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
FNY Investment Advisers, LLC1,000Jun 29, 20220.00%125
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Khiron Life Sciences Corp.


Medical Cannabis Leader Khiron Opens Brazil's First Zerenia™ Clinic

Medical Cannabis Leader Khiron Opens Brazil’s First Zerenia™ Clinic

Khiron is well positioned to expand Zerenia™ clinics in Brazil following its successful introduction in July 2021 of Khiron-branded medical CBD. Dr. Eduardo Faveret, a thought leader and innovator in medical cannabis, has been appointed as Medical Director and will be leading the clinic. Dr. Faveret and the Zerenia™ Rio clinic will be sup... Read More...
Khiron Completes Acquisition of Pharmadrug Production GmbH, Establishing German Pharmaceutical Distribution Capabilities

Khiron Completes Acquisition of Pharmadrug Production GmbH, Establishing German Pharmaceutical Distribution Capabilities

Acquisition provides Khiron with an EU-GMP European manufacturing and distribution hub for medical cannabis and other pharmaceutical products The acquisition of Pharmadrug Production GmbH provides Khiron with direct access to German pharmacies and increase in gross margins for its products With acquisition completed, Khiron will continue... Read More...
Medical Cannabis Innovator Khiron Continues Global Expansion as Industry Leader Throughout Europe and Latin America

Medical Cannabis Innovator Khiron Continues Global Expansion as Industry Leader Throughout Europe and Latin America

Khiron Serves Record Number of Patients With Khiron Products Globally in Its Medical Treatment Clinics TORONTO, June 28, 2022 - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) the global medical cannabis leader, continues expansion of the Khiron end-to-end solution throughout Latin America and Europe. Khiron's g... Read More...
Khiron Life Sciences Announces Closing Of $4.6 Million Overnight Brokered Offering Including Full Exercise Of Over-allotment Option

Khiron Life Sciences Announces Closing Of $4.6 Million Overnight Brokered Offering Including Full Exercise Of Over-allotment Option

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE DISSEMINATION, DISTRIBUTION, RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES/ TORONTO, June 10, 2022 - Khiron Life Sciences Corp. ("Khiron" or, the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), is pleased to announce that it ha... Read More...
Khiron Life Sciences Announces Pricing And Size Of Overnight Brokered Offering

Khiron Life Sciences Announces Pricing And Size Of Overnight Brokered Offering

/NOT FOR ‎DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE ‎DISSEMINATION, DISTRIBUTION, ‎RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES./ TORONTO, June 2, 2022 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce that it has priced and sized it... Read More...
Khiron Life Sciences Announces Overnight Brokered Offering

Khiron Life Sciences Announces Overnight Brokered Offering

/NOT FOR ‎DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE ‎DISSEMINATION, DISTRIBUTION, ‎RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES/ TORONTO, June 1, 2022 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce that it has launched an underwri... Read More...
Khiron to Acquire EU-GMP-Certified German Pharmaceuticals Manufacturer and Wholesaler, Expanding its European Footprint

Khiron to Acquire EU-GMP-Certified German Pharmaceuticals Manufacturer and Wholesaler, Expanding its European Footprint

The acquisition will accelerate Khiron's growth in Europe by controlling the complete value chain for its products and gaining direct access to German pharmacies The acquisition will provide Khiron with an EU GMP-certified European manufacturing and distribution hub for various pharmaceutical products The target is an experienced player ... Read More...
Khiron Life Sciences Reports First Quarter 2022 Financial Results with Record Revenue in Medical Cannabis

Khiron Life Sciences Reports First Quarter 2022 Financial Results with Record Revenue in Medical Cannabis

The Corporation recorded revenues of $4.6 million in Q1 2022, a 65% increase from Q1 2021, and a 28% increase from Q4 2021 Record revenue in medical cannabis of over $2.6 million in Q1 2022, a 470% increase from the prior year and 32% increase from Q4 2021 Gross profit before fair value adjustments grew to $2.1 million, up 96% from Q1 20... Read More...
Khiron to Host First Quarter 2022 Conference Call on May 31, 2022

Khiron to Host First Quarter 2022 Conference Call on May 31, 2022

TORONTO, May 25, 2022 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMXC), the global medical cannabis leader expanding throughout Latin America and Europe, today announces that it will host a Conference Call on Tuesday, May 31, 2022 at 10:00 a.m. Eastern time to discuss its results for the first quarte... Read More...
Khiron achieves United Kingdom Cannabis Sales Volume Growth of 240% in Q1 2022

Khiron achieves United Kingdom Cannabis Sales Volume Growth of 240% in Q1 2022

In Q1 2022, Khiron expects to surpass 1 million CAD in medical cannabis revenues in the United Kingdom ("UK") alone Total untapped potential for cannabis patients in the UK exceeds 1M patients Supported by its clinic in the UK opened in late 2021, Khiron has increased its sales volumes more than 240% in Q1 2022 compared to entire 2021 Kh... Read More...
Khiron to Host YE and Fourth Quarter 2021 Conference Call on May 2, 2022

Khiron to Host YE and Fourth Quarter 2021 Conference Call on May 2, 2022

TORONTO, April 27, 2022 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), the global medical cannabis leader expanding throughout Latin America and Europe, today announces that it will host a conference call on Monday, May 2nd , 2022 at 10:00 a.m. Eastern Time to discuss its financial results for year ... Read More...
Global Medical Cannabis Leader Khiron Opens New Zerenia™ Clinic and Retail Pharmacy in Colombia

Global Medical Cannabis Leader Khiron Opens New Zerenia™ Clinic and Retail Pharmacy in Colombia

Continues market leadership in Colombia, Latin America's only country with universal health coverage for medical cannabis Market leader in the Colombian medical cannabis market, with Q1 2022 volume sales exceeding 21,400 units, up 280% YoY and more than 40% of all 2021 New clinic continues Khiron's unique patient acquisition and retentio... Read More...
Leading Global Medical Cannabis Company Khiron Publishes Clinical Study On The Effectiveness Of Its Products At Controlling Chronic Pain

Leading Global Medical Cannabis Company Khiron Publishes Clinical Study On The Effectiveness Of Its Products At Controlling Chronic Pain

Data Substantiates Company's Position as a Global Leader In Health Care Solutions Key findings in the study include: 9 out of 10 patients reported some degree of improvement of their chronic pain. 7 out of 10 reported an improvement larger than 50% after 4 weeks of treatment. 7 out of 10 patients did not experience any adverse effects re... Read More...
Medical Cannabis Innovator Khiron Continues to Disrupt Global Marketplace Signing Partnership with Teleton in Mexico

Medical Cannabis Innovator Khiron Continues to Disrupt Global Marketplace Signing Partnership with Teleton in Mexico

Teleton has 24 Medical Centers (22 rehabilitation centers, 1 autism center and 1 Children's Hospital for Cancer) located across the country, and around 600,000 patients with disability, cancer and autism conditions The partnership includes: Establishment of Khiron's Zerenia™ medical cannabis clinics within Teleton's network across Mexico... Read More...
Khiron Life Sciences to Present at Upcoming March Investor Conferences

Khiron Life Sciences to Present at Upcoming March Investor Conferences

TORONTO, March 7, 2022 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a medical cannabis leader with core operations in Latin America and Europe, is scheduled to participate in the following virtual and in-person conferences in March 2022: Q1 2022 VIRTUAL INVESTOR SUMMIT March 8 -10, 2022  Khiron Pr... Read More...
Mandatory Insurance Coverage for Medical Cannabis Now Expands to More than 50 million Colombians

Mandatory Insurance Coverage for Medical Cannabis Now Expands to More than 50 million Colombians

Starting January 1st, 2022, every insurance provider in Colombia, is now mandated to cover the costs of high and low THC medical cannabis prescriptions Significantly improves the current insurance coverage process, simplifying the procedure and reducing approval times for patients to obtain insurance coverage across the country Colombi... Read More...
Khiron to Participate in the Lytham Partners Winter 2021 Investor Conference

Khiron to Participate in the Lytham Partners Winter 2021 Investor Conference

TORONTO, Dec. 9, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced today its CEO, Alvaro Torres will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from Decem... Read More...
Khiron Reports Q3 Results - Revenue Increased 83% YoY, 26% QoQ

Khiron Reports Q3 Results – Revenue Increased 83% YoY, 26% QoQ

Q3 2021 revenue increased 83% YoY to $3.5 million compared to the previous year Gross profit before changes in FV in Q3 2021 increased 62% sequentially to $1.7 million Medical cannabis revenues increased 46% sequentially to $1.2 million Continued strong gross margins for medical cannabis segment at 89% TORONTO, Nov. 22, 2021 - Khiro... Read More...
Khiron to Host Third Quarter 2021 Conference Call on November 22, 2021

Khiron to Host Third Quarter 2021 Conference Call on November 22, 2021

TORONTO, Nov. 16, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announces that it will host a conference call on Monday, November 22nd , 2021 at 10:00 a.m. Eastern Time to discuss its resul... Read More...
Khiron Life Sciences to Present at Upcoming November Investor Conferences

Khiron Life Sciences to Present at Upcoming November Investor Conferences

TORONTO, Nov. 8, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is scheduled to participate in the following virtual and in-person conferences in November 2021: CANNABIS EUROPABanking Hall, LondonNovember ... Read More...
Khiron Opens First clinic in Europe with Zerenia™ Clinics UK

Khiron Opens First clinic in Europe with Zerenia™ Clinics UK

Zerenia™ Clinics UK is a specialist medical cannabis clinic in London and another strategic approach by Khiron to improve access to medical cannabis for patients in the UK Hybrid clinic model: Zerenia™ Clinics UK is a digital clinic (www.zereniaclinic.co.uk) and will also offer in-person appointments with medical cannabis specialist pra... Read More...
Khiron reports medical cannabis prescription growth in South America and Europe

Khiron reports medical cannabis prescription growth in South America and Europe

TORONTO, Oct. 4, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated international cannabis leader with core operations in Latin America and Europe, is pleased to provide a corporate update on global medical cannabis operations: Medical Cannabis Latin America Medical cannab... Read More...
Khiron's Announces Resignation of Chief Financial Officer Swapan Kakumanu of RTB LLP appointed as Interim CFO

Khiron’s Announces Resignation of Chief Financial Officer Swapan Kakumanu of RTB LLP appointed as Interim CFO

TORONTO, Oct. 1, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announced that Joel Friedman, has resigned as Chief Financial Officer of the Company for personal reasons. Khiron's board of d... Read More...
Khiron Announces Intention to Renew its Normal Course Issuer Bid

Khiron Announces Intention to Renew its Normal Course Issuer Bid

TORONTO, Sept. 9, 2021 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF) , (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces today its intention to renew its prior normal course issuer bid through the facilities of the TSX Venture Ex... Read More...
Khiron Registers its First Two Medical Cannabis Products in Peru, Available for Sale Nationwide

Khiron Registers its First Two Medical Cannabis Products in Peru, Available for Sale Nationwide

Currently in Peru, the Company sells magistral preparations, or customized compound formulations, through its exclusive agreement with Farmacia Universal. In contrast, as shelf-ready medical cannabis products, Alixen™ 30™ and Alixen™ 100 will be made widely available, on a non-exclusive basis in the country.  Alixen™ 30 will target indic... Read More...
Khiron Reports Q2 Results, 47% QoQ Increase in Medical Cannabis Revenues Driven by Colombia and Germany

Khiron Reports Q2 Results, 47% QoQ Increase in Medical Cannabis Revenues Driven by Colombia and Germany

Q2 2021 revenues of $2.8 million, up 68% YoY Medical cannabis revenues reach $825,500, up 47% sequentially, with sales in Colombia, Germany, UK, and Peru contributing to gross medical cannabis profit margin of 88% European medical cannabis sales growth of 280% sequentially, representing over 25% of total medical cannabis revenues Medi... Read More...
Khiron to Host Second Quarter 2021 Conference Call on August 23, 2021

Khiron to Host Second Quarter 2021 Conference Call on August 23, 2021

TORONTO, Aug. 17, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announces that it will host a conference call on Monday, August 23rd , 2021 at 10:00 a.m. Eastern Time to discuss its results... Read More...
Khiron Publishes Inaugural 2020 ESG Report, Demonstrating Commitment to Sustainability and Continued Market Leadership

Khiron Publishes Inaugural 2020 ESG Report, Demonstrating Commitment to Sustainability and Continued Market Leadership

"At Khiron, sustainability is embedded in our DNA, with the common belief that strong ESG policies improve performance, loyalty, and innovation, while reducing corporate risks and capital costs. Our inaugural ESG report demonstrates our dedication to strong environmental, social and governance principles as we deliver on our Mission of im... Read More...
Colombia Expands Distribution of Medical Cannabis to Pharmacies Nationwide and Opens Export Market for Dried Flower Medical Cannabis

Colombia Expands Distribution of Medical Cannabis to Pharmacies Nationwide and Opens Export Market for Dried Flower Medical Cannabis

On July 23, 2021, the Colombian Government signed Decree 811 of 2021, expanding the regulatory framework for domestic and export medical cannabis markets in Colombia With the Decree, Colombia continues to serve as a regulatory leader and reference point for other countries in the region, having also approved universal insurance coverage... Read More...
Vicente Fox, Khiron Board Member and Former President of Mexico, Applauds Mexican Supreme Court's Advancement of Cannabis Laws

Vicente Fox, Khiron Board Member and Former President of Mexico, Applauds Mexican Supreme Court’s Advancement of Cannabis Laws

Mexico's Supreme Court has voted to decriminalize adult use cannabis, allowing adults to apply for permits to cultivate and consume their own cannabis Khiron reiterates plans to enter Mexican medical cannabis market in 2021 through previously announced clinic and education strategy Recent regulatory and supply chain advances accelerate... Read More...
Khiron Accelerates Entry into Mexico, Awarded High-THC Extract Export Quotas for Mexico by the Government of Colombia

Khiron Accelerates Entry into Mexico, Awarded High-THC Extract Export Quotas for Mexico by the Government of Colombia

With a population close to 130 million people, Mexico is among the top 15 economies worldwide and second largest in Latin America. Approximately 11.7 million people have conditions treatable with medical cannabis (Source: IMS Quintiles) Leveraging its Project of National Strategic Interest (PINES) designation, Khiron receives THC extrac... Read More...
Khiron Opens First Zerenia™ Clinic in Peru, Prescribing High and Low THC Medical Cannabis Products to Patients

Khiron Opens First Zerenia™ Clinic in Peru, Prescribing High and Low THC Medical Cannabis Products to Patients

Khiron launches first Zerenia medical cannabis clinic, via a strategic partnership with Lima-based Clinica Montesur Tweet this Alvaro Torres, CEO and Director comments, "I am pleased to announce the first expansion of our Zerenia brand beyond Colombia. Knowing that prescription rates at our Zerenia clinics are 14 times higher than th... Read More...
Khiron Announces Upcoming Investor Events and Grant of Options and Restricted Share Units

Khiron Announces Upcoming Investor Events and Grant of Options and Restricted Share Units

TORONTO, May 31, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce that the Company´s management will be participating in the following investor: Jefferies Healthcare Confere... Read More...
Coming Soon.
IndexLast% Change
S&P 5004,304.15

0.16%Positive

Euro STOXX 503,805.22

0.41%Positive

FTSE 1007,536.06

0.36%Positive

Nikkei 22528,868.91

0.01%Negative


Delayed data (1h)
IndexLast% Change
S&P 5004,304.15

0.16%Positive

Euro STOXX 503,805.22

0.41%Positive

FTSE 1007,536.06

0.36%Positive

Nikkei 22528,868.91

0.01%Negative



Share this page